A detailed history of Fmr LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Fmr LLC holds 13,286 shares of AVXL stock, worth $90,876. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,286
Previous 1,745 661.38%
Holding current value
$90,876
Previous $8,000 600.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$3.39 - $5.02 $39,123 - $57,935
11,541 Added 661.38%
13,286 $56,000
Q1 2024

May 13, 2024

SELL
$4.55 - $6.75 $34,134 - $50,638
-7,502 Reduced 81.13%
1,745 $8,000
Q4 2023

Feb 13, 2024

BUY
$5.04 - $9.95 $42,315 - $83,540
8,396 Added 986.6%
9,247 $86,000
Q3 2023

Nov 13, 2023

SELL
$6.55 - $9.37 $7,277 - $10,410
-1,111 Reduced 56.63%
851 $5,000
Q2 2023

Aug 11, 2023

BUY
$7.66 - $9.5 $4,304 - $5,339
562 Added 40.14%
1,962 $15,000
Q1 2023

May 11, 2023

BUY
$8.32 - $11.75 $2,812 - $3,971
338 Added 31.83%
1,400 $11,000
Q4 2022

Feb 13, 2023

SELL
$7.65 - $14.43 $4,873 - $9,191
-637 Reduced 37.49%
1,062 $9,000
Q3 2022

Nov 10, 2022

SELL
$8.9 - $12.86 $394,679 - $570,289
-44,346 Reduced 96.31%
1,699 $17,000
Q2 2022

Aug 12, 2022

BUY
$7.31 - $12.84 $2,178 - $3,826
298 Added 0.65%
46,045 $461,000
Q1 2022

May 13, 2022

BUY
$9.74 - $17.69 $445,215 - $808,609
45,710 Added 123540.54%
45,747 $563,000
Q4 2021

Feb 14, 2022

SELL
$16.88 - $23.31 $42,200 - $58,275
-2,500 Reduced 98.54%
37 $1,000
Q3 2021

Nov 15, 2021

BUY
$16.82 - $25.75 $41,915 - $64,169
2,492 Added 5537.78%
2,537 $45,000
Q2 2021

Aug 13, 2021

BUY
$10.16 - $28.86 $457 - $1,298
45 New
45 $1,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $533M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Fmr LLC Portfolio

Follow Fmr LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.